All MUSC Health locations are open. How to help hurricane Helene victims.

Center Awards & Recognition

NCI Designated

A Cancer Center Designated by the National Cancer Institute

MUSC Hollings Cancer Center is one of only 72 cancer centers in the nation — and the only one in South Carolina — to receive a designation from the National Cancer Institute (NCI).

Nationally Ranked

High Performing Hospital | University Medical Center | US News & World Report 2024-2025 | Cancer

MUSC Health University Medical Center is ranked as a high performing hospital for cancer care in the latest U.S. News & World Report rankings. In addition to overall cancer care, University Medical Center was also ranked as high performing for colon cancer surgery, gynecological cancer surgery, leukemia, lymphoma and myeloma, lung cancer surgery and prostate cancer surgery. MUSC Shawn Jenkins Children’s Hospital is #26 on the list of best children's hospitals for cancer.

Magnet Recognition

Magnet recognized American Nurses Credentialing Center badge

MUSC has been awarded with Magnet Recognition®, an acknowledgment of quality patient care, nursing excellence, and innovations in professional nursing practice.

Commission on Cancer

logo that says Commission on Cancer Accredited Program A Quality program of the American College of Surgeons 

In 2022, MUSC Hollings Cancer Center earned a three-year re-accreditation from the Commission on Cancer (CoC), a quality program of the American College of Surgeons (ACS). To achieve CoC re-accreditation, Hollings underwent a site visit to confirm the program’s compliance with accreditation standards that evaluate the cancer care services offered by the program.

As a CoC-accredited cancer center, Hollings applies a multidisciplinary approach and treats cancer as a complex group of diseases that requires consultation among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists, and other health care professionals that specialize in caring for the cancer patient. Cancer patients benefit from having access to clinical trials, screening and prevention events, palliative care, genetic counseling, rehabilitation, oncology nutrition, and survivorship services.

National Accreditation for Radiation Oncology

American College of Radiology Radiation Oncology Accredited Facility logo

The Radiation Oncology team is accredited by the American College of Radiology.

National Accreditation Program for Rectal Cancer

Commission on Cancer National Accreditation Program for Rectal Cancer logo

The Rectal Cancer program is accredited by the National Accreditation Program for Rectal Cancer and is one of a select group of cancer centers across the country to achieve this recognition.

National Accreditation Program for Breast Centers

National Accreditation Program for Breast Centers logo

Our Breast Care program is accredited by the National Accreditation Program for Breast Centers.

Comprehensive Breast Imaging Center

image that says American College of Radiology Designated Comprehensive Breast Imaging Center

Our breast imaging staff was awarded a Comprehensive Breast Imaging Center designation by the American College of Radiology.

Foundation for the Accreditation of Cellular Therapy

Foundation for the Accreditation of Cellular Therapy Accredited logo

The Blood & Marrow Transplant program at Hollings has been accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) since 2003.

Elite GammaTile Center

logo that says Elite GammaTile Therapy Distinguished Brain Tumor Specialists 

MUSC Hollings Cancer Center is the first in South Carolina to achieve Elite GammaTile Center status by completing 10 GammaTile Therapy implant procedures. GammaTile Therapy is a novel Surgically Targeted Radiation Therapy (STaRT) for operable brain tumors. Implanted in the last five minutes of brain tumor removal surgery, each bioresorbable, 3D-collagen GammaTile is embedded with radiation sources. GammaTile Therapy delivers a sustained, controlled, therapeutic radiation dose, targeting tumor cells while sparing healthy tissue.

In the past 50 years, only seven drugs or devices have been FDA-approved or -cleared to treat brain tumors. GammaTile Therapy was FDA-cleared in 2018 for recurrent brain tumors, including recurrent high-grade gliomas, glioblastomas, meningiomas and brain metastases. In 2020, the FDA expanded that indication to include newly diagnosed malignant brain tumors.